Biotech · Private company · San Diego, CA, US
Avidity Biosciences, Inc.
SEC CIK 0001599901
Track this companyFree. Adds Avidity Biosciences, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials115 recruiting or active
Pipeline programs8From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline8
- AOC 1001 (del-desiran)Phase 3 · DM1ClinicalTrials.gov · fetched Nov 12, 2026
- AOC-1020Phase 3 · Facioscapulohumeral Muscular DystrophyClinicalTrials.gov · fetched Nov 12, 2026
- Del-desiran (AOC 1001)Phase 3 · Myotonic Dystrophy Type 1ClinicalTrials.gov · fetched Nov 12, 2026
- AOC 1001Phase 2 · DM1ClinicalTrials.gov · fetched Nov 12, 2026
- AOC 1020Phase 2 · FSHDClinicalTrials.gov · fetched Nov 12, 2026
- AOC 1044Phase 2 · DMDClinicalTrials.gov · fetched Nov 12, 2026
- AOC 1044Phase 2 · Duchenne Muscular DystrophyClinicalTrials.gov · fetched Nov 12, 2026
- delpacibart zotadirsenMuscular Disorders, AtrophicClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials11
- Global Open-Label Extension Study of Del-desiran for the Treatment of DM1PHASE3 · ENROLLING_BY_INVITATION · started Jun 26, 2025ClinicalTrials.gov NCT07008469 · fetched Nov 12, 2026
- A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHDPHASE3 · RECRUITING · started Jun 10, 2025ClinicalTrials.gov NCT07038200 · fetched Nov 12, 2026
- Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)PHASE2 · ACTIVE_NOT_RECRUITING · started Jul 25, 2024ClinicalTrials.gov NCT06547216 · fetched Nov 12, 2026
- Global Study of Del-desiran for the Treatment of DM1PHASE3 · COMPLETED · started May 30, 2024ClinicalTrials.gov NCT06411288 · fetched Nov 12, 2026
- Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With Mutations Amenable to Exon44 SkippingPHASE2 · ACTIVE_NOT_RECRUITING · started Jan 22, 2024ClinicalTrials.gov NCT06244082 · fetched Nov 12, 2026
- Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)PHASE1_PHASE2 · COMPLETED · started Apr 4, 2023ClinicalTrials.gov NCT05747924 · fetched Nov 12, 2026
- Study of AOC 1044 in Healthy Adult Volunteers and Participants With Duchenne Muscular Dystrophy (DMD) Mutations Amenable to Exon 44 SkippingPHASE1_PHASE2 · COMPLETED · started Nov 9, 2022ClinicalTrials.gov NCT05670730 · fetched Nov 12, 2026
- Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) PatientsPHASE2 · COMPLETED · started Aug 4, 2022ClinicalTrials.gov NCT05479981 · fetched Nov 12, 2026
- Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) PatientsPHASE1_PHASE2 · COMPLETED · started Oct 28, 2021ClinicalTrials.gov NCT05027269 · fetched Nov 12, 2026
- Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD)RECRUITING · started Dec 15, 2020ClinicalTrials.gov NCT04635891 · fetched Nov 12, 2026
- Managed Access Program for Del-zota in Participants With DMD Mutations Amenable to Exon 44 SkippingAVAILABLEClinicalTrials.gov NCT07250737 · fetched Nov 12, 2026
SEC filings12
- 8-K · 8-KSEC EDGAR · filed Feb 27, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Feb 26, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Feb 23, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Feb 23, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Feb 3, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Dec 18, 2025 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Nov 10, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 10, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 27, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 14, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 12, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 10, 2025 · fetched Nov 12, 2026